Kalmar Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Kalmar Investments’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-82,715	Closed	-$15.8M	–	153
2015 Q4	$15.8M	Hold	82,715	–	–	0.39%	92
2015 Q3	$12.9M	Hold	82,715	–	–	0.3%	98
2015 Q2	$15M	Hold	82,715	–	–	0.28%	108
2015 Q1	$14.3M	Hold	82,715	–	–	0.27%	117
2014 Q4	$15.3M	Hold	82,715	–	–	0.28%	108
2014 Q3	$13.7M	Hold	82,715	–	–	0.26%	113
2014 Q2	$12.9M	Hold	82,715	–	–	0.22%	125
2014 Q1	$12.6M	Hold	82,715	–	–	0.21%	130
2013 Q4	$11M	Hold	82,715	–	–	0.18%	135
2013 Q3	$9.61M	Hold	82,715	–	–	0.17%	138
2013 Q2	$7.63M	Buy	+82,715	New	+$7.97M	0.15%	141

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Kalmar Investments's ALXN Position: Q1 2016 in Review

Kalmar Investments sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 82,715 shares — an estimated $15.8M sold.

Kalmar Investments first reported a position in ALXN in Q2 2013 and held it in 11 quarters. The position peaked at $15.8M in Q4 2015. 518 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

Kalmar Investments reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Kalmar Investments sold 82,715 Alexion Pharmaceuticals shares in Q1 2016, an estimated $15.8M.
Kalmar Investments first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Kalmar Investments's Alexion Pharmaceuticals position peaked at $15.8M in Q4 2015.
518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Kalmar Investments's 13F filing for Q1 2016, filed 27 May 2016.